FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease

by Dawn C. Matthews, Hedva Lerman, Ana Lukic, Randolph D. Andrews, Anat Mirelman, Miles N. Wernick, Nir Giladi, Stephen C. Strother, Karleyton C. Evans, Jesse M. Cedarbaum, Einat Even-Sapir
Published 2018-01-01

Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models

by Andreas Weihofen, YuTing Liu, Joseph W. Arndt, Christian Huy, Chao Quan, Benjamin A. Smith, Jean-Luc Baeriswyl, Nicole Cavegn, Luzia Senn, Lihe Su, Galina Marsh, Pavan K. Auluck, Fabio Montrasio, Roger M. Nitsch, Warren D. Hirst, Jesse M. Cedarbaum, R. Blake Pepinsky, Jan Grimm, Paul H. Weinreb
Published 2019-04-01

Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science

by Diane Stephenson, Robert Alexander, Varun Aggarwal, Reham Badawy, Lisa Bain, Roopal Bhatnagar, Bastiaan R. Bloem, Babak Boroojerdi, Jackson Burton, Jesse M. Cedarbaum, Josh Cosman, David T. Dexter, Marissa Dockendorf, E. Ray Dorsey, Ariel V. Dowling, Luc J. W. Evers, Katherine Fisher, Mark Frasier, Luis Garcia-Gancedo, Jennifer C. Goldsack, Derek Hill, Janice Hitchcock, Michele T. Hu, Michael P. Lawton, Susan J. Lee, Michael Lindemann, Ken Marek, Nitin Mehrotra, Marjan J. Meinders, Michael Minchik, Lauren Oliva, Klaus Romero, George Roussos, Robert Rubens, Sakshi Sadar, Joseph Scheeren, Eiichi Sengoku, Tanya Simuni, Glenn Stebbins, Kirsten I. Taylor, Beatrice Yang, Neta Zach
Published 2020-11-01